1. Introduction {#s0005}
===============

CTLA-4, a member of the immunoglobulin (Ig) super-family, is a co-stimulatory molecule expressed by activated T cells and has the function of down-regulating T-cell activation ([@bb0050]). CTLA-4 can also induce FAS-independent apoptosis of activated T cells, which may further inhibit immune function of T lymphocytes. A list of mechanisms of CTLA-4 function have been indicated, such as ligand competition with the positive T-cell co-stimulatory CD28 molecule, interference of TCR signaling, and inhibition of cyclin D3 and cyclin-dependent kinase production ([@bb0030]). In tumor-transplanted mice, injection with antibodies that block CTLA-4 function enhanced T cell activation ([@bb0110]), rejected a variety of different tumors, and had long-lasting anti-tumor immunity,([@bb0075]) suggesting that the CTLA-4 plays an important role in carcinogenesis.

The CTLA-4 gene is located on chromosome 2q33, consisting 4 exons that encode separate functional domains: a leader sequence, an extracellular domain, a transmembrane domain, and a cytoplasmic domain ([@bb0090], [@bb0025], [@bb0080]). This gene is polymorphic, more than 100 single nucleotide polymorphisms have been identified ([@bb0105]).An AG dimorphism at position 49 in CTLA-4 exon 1 (rs231775), which causes an amino acid change (threonine to alanine) in the peptide leader sequence of the CTLA-4 protein ([@bb0045]). Recent studies indicated that this polymorphism may influence the ability of CTLA-4 to bind with B7.1 and affect T-cell activation subsequently ([@bb0100], [@bb0115]).

Previous studies have identified that this polymorphism is associated with different cancers including lung cancer, breast cancer, and cervical cancer ([@bb0100], [@bb0020]). However, the results of studies on the association between the + 49A \> G polymorphism and the risk of digestive system cancers remain inconsistent ([@bb0090], [@bb0025], [@bb0100], [@bb0040], [@bb0095], [@bb0015], [@bb0005], [@bb0120], [@bb0035], [@bb0055], [@bb0010], [@bb0060], [@bb0065], [@bb0125], [@bb0070]). To improve the efficiency of meta-analysis on digestive cancers and reduce the potential between-study heterogeneity which might derive from various cancers in diverse systems, we focused on digestive system cancers only and added more recent studies in this meta-analysis.

2. Search strategy {#s0010}
==================

In this meta-analysis, a comprehensive literature research of the US National Library of Medicine\'s Pub Med database, ISI Web of Knowledge, Medline, Embase and Google Scholar Search (update to August, 2014) were conducted using the search terms including "CTLA-4", "polymorphisms", "cancer", and the combined phrases in order to obtain all genetic studies on the relationship of CTLA-4 + 49G/A polymorphism and cancer. We also used a hand search of references of original studies or reviewed articles on this topic to identify additional studies. The following criteria were used to select the eligible studies: (1) a case--control study on the association between CTLA-4 + 49G/A polymorphism and cancer, (2) detailed number of different genotypes for estimating an odds ratio (OR) with 95% confidence interval (3) when several publications reported on the same population data, the largest or most complete study was chosen.

3. Data extraction {#s0015}
==================

Data extraction was carried out independently by two investigators after the concealment of authors, journals, supporting organizations and funds to avoid investigators\' bias. For each eligible study, the following information was recorded: the first author\'s name, the year of publication, country of origin, cancer type, genotyping method, sources of controls, racial descent of the study population, number of cases and number of controls with different allele frequencies.

4. Statistical analysis {#s0020}
=======================

The strength of relationship between CTLA-4 + 49G/A polymorphism and cancer was assessed by using Crude OR with 95% CI. We examined the association between the CTLA-4 + 49G/A polymorphism and digestive cancer risks using the following genetic contrasts: homozygote comparison (GG vs. AA), heterozygote comparison (GA vs. AA), dominant genetic model (GG + GA vs. AA), recessive genetic model (GG vs. GA + AA) and allelic comparison (G vs. A). Between-study heterogeneity was evaluated by Q-test. Fixed effects model was used to pool the data when the P-value of Q-test ≥ 0.05, otherwise, random- effects model was selected. Both funnel plot and Egger\'s test were used to assess the publication bias (P \< 0.05 was considered representative of statistical significance). All statistical analyses were performed using STATA11.0 software and Review Manage (v.5; Oxford, England).

5. Results {#s0025}
==========

5.1. Eligible studies {#s0030}
---------------------

By the inclusion and exclusion criteria, 17 relevant studies involving 5176 cases and 6747 controls were selected in this meta-analysis. The main characteristics of these studies are shown in [Table 1](#t0005){ref-type="table"}. Genotype distribution of the CTLA-4 + 49G/A polymorphism among cancer cases and controls of the 17 studies are shown in [Table 2](#t0010){ref-type="table"}. All studies were case--control studies, including five colorectal cancer studies, four gastric cancer studies, two esophageal cancer studies, two hepatocellular cell carcinoma studies, two oral cancer studies and two pancreatic cancer studies. There were 12 studies of Asian descent and five studies of Caucasian descent. Hospital based controls were carried out in 12 studies, while population based controls were carried out in 5 studies. The genotyping method contains the classic polymerase chain reaction--restriction fragment length polymorphism (PCR-RFLP) assay, RFLP and TaqMan. The distribution of genotypes in the controls was all in agreement with HWE.

5.2. Meta-analysis {#s0035}
------------------

The association strength between CTLA-4 + 49G/A polymorphism and the susceptibility for digestive system cancers are shown in [Table 3](#t0015){ref-type="table"}. Overall, there was no statistically increased risk of digestive system cancers in every genetic comparison (GG vs. AA, OR = 1.217, 95% CI = 0.923--1.605; GA vs. AA, OR = 1.160, 95% CI = 0.991--1.362; GG/GA vs. AA, OR = 1.165, 95% CI = 0.932--1.456; GG vs. GA/AA, OR = 0.897, 95% CI = 0.762--1.054; G vs. A, OR = 0.966, 95% CI = 0.829--1.126).

We then evaluated the effects of CTLA-4 + 49G/A polymorphism according to specific cancer types, different ethnicities and different sources of control. As shown in [Table 3](#t0015){ref-type="table"}, we demonstrated that this locus polymorphism was significantly linked to higher risks for pancreatic cancer (GG vs. AA, OR = 1.976, 95% CI = 1.496--2.611; GA vs. AA, OR = 1.433, 95% CI = 1.093--1.879; GG/GA vs. AA, OR = 1.668, 95% CI = 1.286--2.164; GG vs. GA/AA, OR = 1.502, 95% CI = 1.098--2.054; G vs. A, OR = 1.394, 95% CI = 1.098--1.770). We also observed increased susceptibility of hepatocellular cell carcinoma in homozygote comparison (OR = 1.433, 95% CI = 1.100--1.866) and dominant model (OR = 1.360, 95% CI = 1.059--1.746). Furthermore, we observed increased susceptibility of esophageal cancer only in heterozygote comparison (OR = 1.454, 95% CI = 1.110--1.906). No significant associations were found in colorectal cancer, gastric cancer and oral cancer.

According to the source of controls, significant effects were observed in hospital-based studies (GA/AA vs. GG, OR = 1.257, 95% CI = 1.129--1.399), but in population-based studies, no significant association was observed in all models. In the stratified analysis by ethnicity, no significantly increased risks were found in either Asian or Caucasian.

6. Publication bias {#s0040}
===================

Both Begg\'s funnel plot and Egger\'s test were performed to assess the publication bias of the literature. The shape of the funnel plots did not reveal any evidence of obvious asymmetry in the overall meta-analysis ([Fig. 1](#f0005){ref-type="fig"} shows the funnel plot of overall GG vs. AA). Then, Egger\'s test was used to provide statistical evidence of funnel plot symmetry. The results still did not present any obvious evidence of publication bias in the subgroup analyses.

7. Discussion {#s0045}
=============

The result of this meta-analysis suggested that CTLA-4 + 49G/A polymorphism was significantly linked to higher risks for pancreatic cancer. Besides, the polymorphism was associated with an increased risk of developing hepatocellular cell carcinoma. The CTLA-4 49G \> A SNP has been linked to elevated risk of breast cancer in an Iranian population ([@bb0025]), and non-Hodgkin\'s lymphoma in a European Caucasian population ([@bb0070]). In addition, two more studies suggested that this polymorphism is associated with different cancers including lung cancer and cervical cancer ([@bb0100], [@bb0065]). A meta-analysis conducted by Zheng et al. suggested that the CTLA-4 + 49G/A polymorphism was associated with an increased risk of developing solid tumors (including lung caner, breast cancer, colorectal cancer, gastric cancer, skin cancer, thymoma, nasopharyngeal carcinoma, cervical squamous cell carcinoma, esophageal cancer, oral squamous cell carcinoma, HBV-related hepatocellular carcinoma, and renal cell cancer) ([@bb0085]). Interestingly, Yonggang Zhang et al. conducted a meta-analysis and the results indicated that the polymorphism is associated with a decreased risk of lung cancer and breast cancer but not of cervical cancer, colorectal cancer, or gastric cancer ([@bb0130]).

In our analysis, we first reported that there was no statistically increased risk between the CTLA-4 + 49G/A polymorphism and digestive system cancers. In subgroup analysis, we observed that this polymorphism was significantly linked to higher risks for pancreatic cancer. We also observed the CTLA-4 + 49G/A polymorphism was associated with an increased risk of developing hepatocellular cell carcinoma but not gastric cancer, colorectal cancer and oral cancer. However, all of these results should be interpreted with caution. On condition that, for some cancer types, only two case--control studies were included, which may have limited power to reveal a reliable association. Furthermore, we observed inconsistent results between hospital-based studies and population-based studies, which may be explained by the biases brought by hospital-based studies. Controls in hospital-based studies may be less representative of general population than controls from population-based studies.

There were some limitations in our meta-analysis. Firstly, sample size in any given cancer was not sufficiently large. It might be difficult to get a concrete conclusion if the number of included studies in subgroup was few. Secondly, due to the original data of the eligible studies were unavailable, it is difficult for us to evaluate the roles of some special environmental factors and lifestyles such as diet, alcohol consumption, and smoking status in developing cancer. And thirdly, language bias might derive from the screened references of English documents only.

In conclusion, our meta-analysis suggested that the CTLA-4 + 49G/A polymorphism may be not associated with an elevated digestive system cancer risks. Large well-designed epidemiological studies are needed to validate our findings.

Conflict of interest {#s0050}
====================

None.

The authors will thank Dr. Pan Xiangpo for his great help in revising this article.

![The funnel plot of overall GG vs. AA.](gr1){#f0005}

###### 

Main characteristics of included studies in the meta-analysis.

  Author     Year   Type             Ethnicity   Country   Genotye assay    Source of control   Cases   Controls
  ---------- ------ ---------------- ----------- --------- ---------------- ------------------- ------- ----------
  Yang       2012   Pancreatic       Asian       China     PCR-RFLP         Population          926     368
  Lang       2012   Pancreatic       Asian       China     PCR-RFLP         Population          651     602
  Cheng      2011   Esophagus        Asian       China     PCR-RFLP         Population          205     205
  Cozar      2007   Colon            European    Spain     TaqMan           Hospital            176     221
  Dilmec     2008   Colorectal       European    Turkey    RFLP             Hospital            162     56
  Gu         2010   Hepatocellular   Asian       China     PCR-LDR          Hospital            367     407
  Hadinia    2007   Colorectal       Asian       Iran      RFLP, PCR-ARMS   Hospital            190     105
  Hadinia    2007   Gastric          Asian       Iran      RFLP, PCR-ARMS   Hospital            190     43
  Hu         2010   Hepatocellular   Asian       China     TaqMan           Population          854     853
  Hou        2010   Gastric          Asian       China     PCR-ARMS         NA                  205     262
  Kammerer   2010   Oral             European    German    RT-PCR           Hospital            40      83
  Mahajan    2008   Gastric          European    Poland    TaqMan           Population          411     301
  Qi         2010   Colorectal       Asian       China     PCR-LDR          NA                  124     407
  Solerio    2005   Colorectal       European    Italy     RFLP             Hospital            238     132
  Sun        2008   Esophagus        Asian       China     RFLP             Hospital            1008    1010
  Sun        2008   Gastric          Asian       China     RFLP             Hospital            530     530
  Wong       2006   Oral             Asian       China     RFLP             Hospital            147     118

###### 

Distribution of CTLA-4 + 49G/A polymorphism among cancer cases and controls in this meta-analysis.

  Author     Year   Type             AA (control)   AG (control)   GG (control)   AA (case)   AG (case)   GG (case)   G (control)   A (control)   G (case)   A (case)   HWE
  ---------- ------ ---------------- -------------- -------------- -------------- ----------- ----------- ----------- ------------- ------------- ---------- ---------- -----
  Gu         2010   Hepatocellular   51             166            150            45          179         183         268           466           269        545        Yes
  Hu         2010   Hepatocellular   106            380            367            79          376         399         592           1114          534        1174       Yes
  Hadinia    2007   Gastric          24             13             6              117         59          14          25            61            87         293        Yes
  Mahajan    2008   Gastric          89             153            59             152         189         70          331           271           493        329        Yes
  Hou        2010   Gastric          100            55             107            41          70          94          269           255           258        152        Yes
  Sun        2008   Gastric          60             235            235            39          209         282         355           705           287        773        Yes
  Qi         2010   Colorectal       4              60             60             45          179         183         68            180           269        545        Yes
  Solerio    2005   Colorectal       76             43             13             128         91          19          195           69            347        129        Yes
  Hadinia    2007   Colonrectal      52             47             6              117         59          14          59            151           87         293        Yes
  Cozar      2007   Colorectal       119            87             15             78          77          21          325           117           233        119        Yes
  Dilmec     2008   Colorectal       36             19             1              108         43          11          21            91            65         259        Yes
  Cheng      2011   Esphogaous       36             79             90             46          105         54          259           151           213        197        Yes
  Sun        2008   Esphogaous       128            434            448            73          406         529         690           1330          552        1464       Yes
  Kammerer   2010   Oral             35             32             16             11          23          6           102           64            45         35         Yes
  Wong       2006   Oral             12             58             48             25          64          58          82            154           114        180        Yes
  Yang       2012   Pancreatric      50             178            140            70          374         482         458           278           1338       514        Yes
  Lang       2012   Pancreatic       82             312            208            62          326         263         728           476           852        450        Yes

###### 

Results of this meta-analysis for the CTLA-4 + 49G/A polymorphism and digestive cancer risks.

  Study groups        *N* \*   GG vs.AA                 GA vs. AA   GG/GA vs. AA            GG vs. GA/AA   G vs A                                                                                          
  ------------------- -------- ------------------------ ----------- ----------------------- -------------- ----------------------- ---------- ------------------------ ---------- ------------------------ ----------
  All population      17       1.217 (0.923--1.605) ‡   \< 0.001    1.160(0.991--1.362) ‡   \< 0.001       1.165(0.932--1.456) ‡   \< 0.001   0.897(0.762--1.054) ‡    \< 0.001   0.966(0.829--1.126) ‡    \< 0.001
                                                                                                                                                                                                           
  Cancer type                                                                                                                                                                                              
  Hepatocellular      2        1.433(1.100--1.866)†     0.851       1.291(0.992--1.681)     0.771          1.360(1.059--1.746)†    0.796      0.856(0.731--1.004)      0.920      0.857(0.761--0.964)†     0.983
  Gastric             4        1.160(0.601--2.237)‡     \< 0.001    1.300(0.670--2.521)‡    \< 0.001       1.235(0.662--2.302)‡    \< 0.001   0.928 (0.663--1.299) ‡   0.042      1.033(0.696--1.532) ‡    \< 0.001
  Colorectal          5        1.028(0.479--2.207)‡     0.020       0.805 (0.498--1.301)‡   0.006          0.858(0.543--1.354)‡    0.006      0.927 (0.691--1.243)     0.215      0.929(0.727--1.188)‡     0.060
  Esophagus           2        1.004(0.235--4.291)‡     \< 0.001    1.454(1.110--1.906)†    0.146          1.194(0.482--2.957)‡    0.002      1.236 (0.417--3.664)‡    \< 0.001   0.708(0.627--0.799)†     0.368
  Oral                2        0.725(0.379--1.385)      0.312       1.086 (0.259--4.554)‡   0.013          1.017(0.300--3.449)‡    0.026      1.141 (0.733--1.777)     0.478      1.058(0.786--1.424)      0.240
  Pancreatic          2        1.976(1.496--2.611)†     0.173       1.433(1.093--1.879)†    0.766          1.668(1.286--2.164)†    0.347      0.666 (0.487--0.911)†‡   0.063      1.394 (1.098--1.770)†‡   0.049
                                                                                                                                                                                                           
  Ethnicity                                                                                                                                                                                                
  Asian               12       1.240(0.908--1.695)‡     \< 0.001    1.164 (0.895--1.514)‡   \< 0.001       1.179(0.896--1.551)‡    \< 0.001   0.878 (0.738--1.046)‡    \< 0.001   0.974(0.807--1.175)‡     \< 0.001
  European            5        1.143(0.660--1.977)‡     0.070       0.988 (0.699--1.397)‡   0.070          1.101(0.776--1.562)‡    0.029      1.015 (0.763--1.351)     0.154      0.951(0.745--1.213)      0.053
                                                                                                                                                                                                           
  Source of control                                                                                                                                                                                        
  Population-based    5        1.169(0.694--1.970)‡     \< 0.001    1.156 (0.873--1.530)‡   0.029          1.170(0.800--1.712)‡    \< 0.001   0.965 (0.678--1.373)‡    \< 0.001   1.063(0.802--1.408)‡     \< 0.001
  Hospital-based      12       1.255(0.901--1.749)‡     0.001       1.125(0.828--1.530)‡    \< 0.001       1.154(0.864--1.541)‡    \< 0.001   0.796 (0.715--0.886)†    0.150      0.919(0.778--1.086)‡     \< 0.001

[^1]: Liu Xiaolei and Pan Xiangpo contributed to this work equally.
